
NASDAQ:VRTX
This summary was created by AI, based on 2 opinions in the last 12 months.
Vertex Pharmaceuticals Inc. has emerged as a leading player in the pharmaceutical industry, particularly known for its advancements in cystic fibrosis treatment. The company has not only developed drugs that have become the standard of care for cystic fibrosis, but has also ventured into innovative gene therapies, showcasing its commitment to cutting-edge science. Recent reviews indicate that Vertex is thriving and has revitalized its operations, moving away from past dormancy. Experts highlight the efficacy of Vertex's treatments and its strong position in several therapeutic areas, making it a formidable entity in the pharma domain. With a focus on improving patient outcomes through innovative therapies, Vertex appears to be on a growth trajectory in the industry.
Vertex Pharmaceuticals Inc. is a American stock, trading under the symbol VRTX (previously VRTX-Q on Stockchase) on the NASDAQ (VRTX). It is usually referred to as NASDAQ:VRTX or VRTX
In the last year, 2 stock analysts issued a Buy, Sell, or Hold rating on VRTX (previously VRTX-Q on Stockchase). 2 analysts recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is BUY. Read the latest stock experts' ratings for Vertex Pharmaceuticals Inc..
Vertex Pharmaceuticals Inc. was recommended as a Top Pick by Jim Lebenthal on 2026-06-29. Read the latest stock experts ratings for Vertex Pharmaceuticals Inc..
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Vertex Pharmaceuticals Inc..
Vertex Pharmaceuticals Inc. is followed by 78 investors on Stockchase and is a trending stock that is worth watching.
On 2026-07-23, Vertex Pharmaceuticals Inc. (VRTX) stock closed at a price of $474.24.
Pharma is a great place to be now after being dormant. Vertex owns a cystic fibrosis channel and thriving in other therapeutic areas.